Evaluation of the Cardiovascular Risk of Naltrexone-Bupropion: A Study Interrupted

JAMA. 2016 Mar 8;315(10):984-6. doi: 10.1001/jama.2016.1461.

Authors

Joshua M Sharfstein¹, Bruce M Psaty²

Affiliations

¹ Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
² Cardiovascular Health Research Unit, Departments of Medicine, Epidemiology, and Health Services, University of Washington, Seattle3Group Health Research Institute, Group Health Cooperative, Seattle, Washington.

PMID: 26954405
DOI: 10.1001/jama.2016.1461

No abstract available

Publication types

Editorial
Research Support, N.I.H., Extramural
Comment

MeSH terms

Anti-Obesity Agents / adverse effects*
Bupropion / adverse effects*
Cardiovascular Diseases / chemically induced*
Early Termination of Clinical Trials*
Female
Humans
Male
Naltrexone / adverse effects*
Obesity / drug therapy*

Substances

Anti-Obesity Agents
Bupropion
Naltrexone

Grants and funding